Delivery Order SPE2DR25D9114-SPE2DR26FMDY4
- Not listed
- The Defense Logistics Agency awarded a $48,462.60 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count packages). The contract, executed on October 31, 2025, with an ultimate completion date of November 3, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award was issued under DMS Pharmaceutical Group's single-award...
- The Defense Logistics Agency awarded a delivery order valued at $24,793.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for supply of JAKAFI 5 mg tablets (60-count packages). The contract is a firm fixed-price delivery order with no set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The ultimate completion date is November 19, 2025, with...
- The Defense Logistics Agency awarded a $258,404.76 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count units). The delivery order, issued on December 4, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation, indicating the award was made through unrestricted federal procurement. DMS Pharmaceutical Group Inc. is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Jakafi 10 mg tablets (60-count). This firm fixed-price delivery order, issued on December 9, 2025, with an ultimate completion date of December 10, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The award is...
- The Defense Logistics Agency awarded a delivery order valued at $24,793.16 to DMS Pharmaceutical Group Inc. for 60 tablets of JAKAFI 5 MG on December 1, 2025, with an ultimate completion date of December 2, 2025. This firm fixed-price delivery order was issued without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,396.58 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 5 mg tablets (60 count). This firm fixed-price delivery order, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, was awarded without a set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS...
- The Defense Logistics Agency awarded a delivery order valued at $12,338.41 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of JAKAFI 20 mg tablets (60-count units). This firm fixed-price delivery order was issued on October 29, 2025, with an ultimate completion date of October 30, 2025, and does not utilize a set-aside designation. The award reflects DMS Pharmaceutical Group's competitive capability to...
- The Defense Logistics Agency awarded a delivery order valued at $12,115.65 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count units). This firm fixed-price delivery order, issued on October 21, 2025, with an ultimate completion date of October 22, 2025, carries no set-aside designation, demonstrating the contractor's ability to compete effectively in unrestricted...
- The Defense Logistics Agency awarded a $54,115.79 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of JAKAFI 10 mg. The award, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform the...
- The Defense Logistics Agency awarded a delivery order valued at $36,739.74 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of JAKAFI 15 mg tablets (60-count units). The award, issued on December 8, 2025, with an ultimate completion date of December 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating the vendor competed in an unrestricted procurement...
- SPE2DR25D9114Indefinite Delivery Contract
- SPE2DR25D9114-SPE2DR26FMDY4Delivery Order
The Defense Logistics Agency (DLA) awarded a $99,172.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 60 tablets of JAKAFI 5 mg. This delivery order, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, and DMS Pharmaceutical Group will serve as the prime contractor with no identified subcontractors on this award. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that was awarded to the contractor on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. The PPV-G GEN V program establishes multiple regional prime vendor contractors to supply a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to support Department of Defense military healthcare facilities globally. JAKAFI (ruxolitinib) is a specialty pharmaceutical used in the treatment of myelofibrosis and other conditions, aligning with DMS Pharmaceutical Group's demonstrated portfolio of specialty pharmaceuticals and oncology treatments supplied to the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $99.2k | 11/23/25 |